U.S. Markets open in 3 hrs 13 mins

C. R. Bard, Inc. (BCR)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
320.30-0.53 (-0.17%)
At close: 4:02PM EDT
People also watch
BDXBMSDOVCTASCINF

C. R. Bard, Inc.

730 Central Avenue
Murray Hill, NJ 07974
United States
908-277-8000
http://www.crbard.com

SectorHealthcare
IndustryMedical Instruments & Supplies
Full Time Employees16,300

Key Executives

NameTitlePayExercisedAge
Mr. Timothy M. RingChairman and Chief Exec. Officer3.77M28.92M59
Mr. John H. WeilandVice Chairman, Pres and Chief Operating Officer2.89M1.36M61
Mr. Christopher S. HollandChief Financial Officer and Sr. VP1.6M949.03k51
Mr. Timothy P. CollinsGroup Pres1.89MN/A56
Mr. Jim C. BeasleyGroup Pres1.87M1.71M53
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

C. R. Bard, Inc., together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and a range of minimally invasive devices for the treatment of peripheral vascular and end-stage renal diseases. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for the treatment of prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal procedures; surgical slings and pelvic floor repair products; catheter stabilization devices; and products for therapeutic hypothermia. In addition, the company offers oncology products, such as specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters, and enteral feeding devices to treat and manage various cancers, and other diseases and disorders. Further, it provides surgical specialty products comprising implanted grafts and fixation devices for hernia and soft tissue repairs; and hemostats and surgical sealants, as well as irrigation, wound drainage, and original equipment manufacturers’ products. The company sells its products directly to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities through hospital/surgical supply and other medical specialty distributors. C. R. Bard, Inc. was founded in 1907 and is headquartered in Murray Hill, New Jersey.

Corporate Governance

C. R. Bard, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 5. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 5; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.